A randomised trial of glucose tablets to aid smoking cessation

West, Robert; May, Sylvia; McEwen, Andy; McRobbie, Hayden; Hájek, Peter; Vangeli, Eleni

doi:10.1007/s00213-009-1692-3

Cited by 12 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dear Editor, West et al (2010) reported that glucose tablets alone were no better than placebo in helping smokers to quit (11% vs 14%). However, among smokers also using an approved smoking cessation medicine (nicotine replacement or bupropion), glucose tablets increased their 6-month quit rate (18.2% vs 12.6%, p<0.05).…”

mentioning

confidence: 96%

Blood glucose levels produced by glucose tablets in abstaining smokers

Foulds¹,

Parth

Bover-Manderski³

2010

Psychopharmacology

View full text Add to dashboard Cite

mentioning

confidence: 96%

Blood glucose levels produced by glucose tablets in abstaining smokers

Foulds¹,

Parth

Bover-Manderski³

2010

Psychopharmacology

View full text Add to dashboard Cite

“…It was hypothesised that glucose tablets could promote abstinence by satiating carbohydrate cravings that ex-smokers often mislabelled as cigarette cravings [146,147]. Previous studies have shown that nicotine acts as an acute appetite suppressant by raising blood glucose levels and acting directly on cells in the lateral hypothalamus.…”

Section: Glucose Tabletsmentioning

confidence: 99%

“…In a randomised controlled trial with nearly one thousand participants, no significant effect of glucose tablets over and above sweet tasting tablets was detected [147]. However, glucose tablets may promote short-term abstinence, particularly when used as an adjunct to NRT or bupropion [147,148].…”

Section: Relative Efficacymentioning

confidence: 99%

“…Glucose is unlikely to interact with other medications and so may be used concurrently [147]. It is freely available and has no contraindications (except some caution should be advised for those with diabetes).…”

Section: Relative Scopementioning

confidence: 99%

“…However, glucose tablets may promote short-term abstinence, particularly when used as an adjunct to NRT or bupropion [147,148].…”

Section: Relative Efficacymentioning

confidence: 99%

See 2 more Smart Citations

New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

et al. 2016

Self Cite

View full text Add to dashboard Cite

A wide range of support is available to help smokers to quit and aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion. Despite the efficacy of these, there is a continual need to diversify the range of medications so that the needs of tobacco users are met. This paper compares the first-line smoking cessation medications to: 1) two variants of these existing products: new galenic formulations of varenicline and novel nicotine delivery devices; and 2) twenty-four alternative products: cytisine (novel outside of central and eastern Europe), nortriptyline, other tricyclic antidepressants, electronic cigarettes, clonidine (an anxiolytic), other anxiolytics (e.g. buspirone), selective 5-hydroxytryptamine Key points: This paper reviews 26 pharmacotherapies that have been investigated for tobacco harm reduction and smoking cessation alongside three first-line treatments (nicotine replacement therapy, varenicline and bupropion) on six criteria: relative efficacy, relative safety, relative cost, relative use, relative scope, and relative ease of use. Although many of these products are in the early stages of clinical trials, of all the medications considered, cytisine appears to offers the best prospect for the future, having established safety and efficacy and being very inexpensive. Electronic cigarettes have become very popular in some countries but efficacy and long-term safety compared with other treatment profiles require further consideration.

show abstract